25 August 2026
Pipeline still favors weekly pens
Prime Therapeutics dated August 25, 2026 listed Novo Nordisk’s injectable fixed-dose combination of semaglutide and cagrilintide for weight loss with an FDA decision expected in December 2026.
The full briefing is in the app.